[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Sethom A, Akkari K, Hachicha A, Bahri W, Miled I, Benzarti S, Kamel Chebbi M: [Ear nose sarcoma. Report of 3 cases]. Tunis Med; 2010 Jun;88(6):440-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ear nose sarcoma. Report of 3 cases].
  • [Transliterated title] Les Sarcomes à localisation ORL. (A propos de 3 Observations).
  • BACKGROUND: Head and neck sarcoma are very rare malignant tumors which can occur on any different ENT localization.
  • We intend to remind of clinical and histological particularities, therapeutic modalities and finally to evaluate the follow-up.
  • In each case, diagnosis was validated by the immunohistochemistry.
  • All patients had surgical removal of their tumor.
  • External irradiation or/and chemotherapy was also indicated for all cases.
  • CONCLUSION: ENT sarcomas are aggressive neoplasm.
  • [MeSH-major] Otorhinolaryngologic Neoplasms / diagnosis. Sarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20517859.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


2. Héran F, Williams M, Ayache D: [MRI of the temporal bone]. J Radiol; 2006 Nov;87(11 Pt 2):1783-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors and malignant otitis externa are the most common lesions of the external auditory canal.
  • MRI features of cholesteatoma redux, transtegmental masses, and paragangliomas are described in the middle ear MRI study.
  • The diagnosis of petrous apex abnormalities is emphasized: cholesterol granuloma, malignant tumor, epidermoid cyst, cholesteatoma, and petrositis.
  • [MeSH-major] Cholesteatoma, Middle Ear / diagnosis. Fibrous Dysplasia of Bone / diagnosis. Labyrinthitis / diagnosis. Magnetic Resonance Imaging. Neuroma, Acoustic / diagnosis. Otitis Externa / diagnosis. Skull Neoplasms / diagnosis. Temporal Bone
  • [MeSH-minor] Anticoagulants / therapeutic use. Cholesterol. Diagnosis, Differential. Epidermal Cyst / diagnosis. Follow-Up Studies. Granuloma, Foreign-Body / diagnosis. Hematoma / drug therapy. Hematoma / etiology. Humans. Male. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Middle Aged. Petrous Bone. Postoperative Complications. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124479.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticoagulants; 97C5T2UQ7J / Cholesterol
  • [Number-of-references] 30
  •  go-up   go-down


3. Park SY, Kim JH, Kim KT, Kim YJ, Kim TH, Hwang K, Sung KJ, Park KH: A case of medullomyoblastoma of cerebellopontine angle mimicking acoustic neuroma. Yonsei Med J; 2004 Aug 31;45(4):719-22
MedlinePlus Health Information. consumer health - Acoustic Neuroma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medulloblastoma is a common malignant central nervous system neoplasm found mainly in children.
  • One the contrary, medulloblastoma of the cerebellopontine angle, the location of the tumor is very unusual.
  • A 15-year-old boy experienced a sudden hearing loss in the left ear.
  • Conservative medical treatment failed, and temporal MR imaging revealed a heterogeneously enhancing mass at the left cerebellopontine angle cistern and in the internal auditory canal; therefore, the lesion was regarded as a typical acoustic neuroma.
  • Few days before surgery, an ipsilateral facial palsy developed, and a follow-up MR imaging showed a rapid growth of the previous lesion.
  • And under pathological diagnosis of malignancy, radiation therapy and series of chemotherapy was performed.
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15344215.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


Advertisement
4. Mula V, Mandal A, Britton E, Shanker VS: Direct bony invasion of malignant melanoma. Indian J Orthop; 2009 Oct;43(4):420-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct bony invasion of malignant melanoma.
  • Malignant melanoma is known to spread by local extention, by the lymphatics by the blood stream.
  • Histopathology diagnosed the lesion as locally advanced malignant melanoma.
  • Radiological investigations by X-ray and magnetic resonance imaging revealed malignant infiltration of the tibia in its mid and lower third with two soft tissue metastatic masses adjacent.
  • Histology following amputation confirmed malignant melanoma with cranial resection margin involvement.
  • She underwent a further above-knee amputation followed by chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orthopedics. 2001 Mar;24(3):225, 307-8 [11300284.001]
  • [Cites] J Bone Joint Surg Am. 2001 Nov;83-A(11):1713-7 [11701796.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1780-4 [11100057.001]
  • [Cites] J Laryngol Otol. 2000 May;114(5):378-80 [10912271.001]
  • [Cites] Can J Surg. 2000 Apr;43(2):137-9 [10812349.001]
  • [Cites] J Hand Surg Am. 2000 Mar;25(2):365-9 [10722831.001]
  • [Cites] Int J Clin Oncol. 2007 Aug;12(4):305-8 [17701013.001]
  • [Cites] Ear Nose Throat J. 2007 Jul;86(7):388-90 [17702316.001]
  • [Cites] J Cutan Med Surg. 2006 Jan-Feb;10(1):36-40 [17241571.001]
  • [Cites] Europace. 2006 Jul;8(7):545-8 [16798769.001]
  • [Cites] Am Surg. 2006 Jan;72(1):98-100 [16494196.001]
  • [Cites] J Hand Surg Am. 2005 May;30(3):615-9 [15925176.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):336-44 [10379853.001]
  • [Cites] Arch Pathol Lab Med. 1999 Feb;123(2):163-6 [10050793.001]
  • [Cites] J Laryngol Otol. 2004 May;118(5):382-4 [15165318.001]
  • [Cites] J Hand Surg Am. 2004 Mar;29(2):194-200 [15043888.001]
  • [Cites] Clin Nucl Med. 2003 Dec;28(12):961-5 [14663316.001]
  • [Cites] Mol Imaging Biol. 2002 Oct;4(5):359-62 [14537111.001]
  • [Cites] Rom J Gastroenterol. 2002 Mar;11(1):53-6 [12096315.001]
  • [Cites] J Hand Surg Am. 2000 Nov;25(6):1169-72 [11119681.001]
  • (PMID = 19838397.001).
  • [ISSN] 1998-3727
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2762569
  • [Keywords] NOTNLM ; Bone tumor / direct invasion / malignant melanoma / metastatic melanoma
  •  go-up   go-down


5. Sparano A, Kreiger P, Kazahaya K: Malignant rhabdoid tumor of the parapharyngeal space. Ear Nose Throat J; 2009 Mar;88(3):E24-6
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant rhabdoid tumor of the parapharyngeal space.
  • Malignant rhabdoid tumor has been a somewhat controversial entity since it was first described in 1978 as a possible sarcomatous variant of Wilms tumor.
  • Eventually, however, it was found to be a distinct neoplastic tumor with histologic characteristics similar to those of rhabdomyosarcoma.
  • Malignant rhabdoid tumors affect children.
  • Associated mortality is significant, even with combined-modality treatment regimens.
  • We describe the case of a large extrarenal malignant rhabdoid tumor of the parapharyngeal space with extension to the infratemporal fossa and skull base in a previously healthy 2-year-old girl who had presented with a cervical mass and ipsilateral Horner syndrome.
  • The patient underwent complete surgical extirpation of the lesion and received adjunctive cisplatin chemotherapy and radiation therapy, and she remained disease-free at 9 months of follow-up.
  • Given the age group of the patients that these neoplasms most commonly affect and given the neoplasms' resemblance to rhabdomyosarcoma and other small round-cell tumors of the head and neck, discussion of the associated clinical pathology, imaging characteristics, histopathologic features, and mode of management are of particular importance, especially so in view of the uncommon location of the tumor in this specific case.
  • Such a discussion may help lead to minimization of misdiagnosis and maximization of therapeutic benefit.
  • [MeSH-major] Pharyngeal Neoplasms / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Child, Preschool. Female. Humans. Necrosis / pathology. Voice Disorders / diagnosis. Voice Disorders / etiology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19291622.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Liao HT, Chien CH, Chen CH, Wang HP, Huang DF: Recurrent autoimmune inner ear disease (AIED) and polyarteritis nodosa in a patient with large cell lung carcinoma. Clin Rheumatol; 2007 Jun;26(6):1008-10
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent autoimmune inner ear disease (AIED) and polyarteritis nodosa in a patient with large cell lung carcinoma.
  • Autoimmune inner ear disease (AIED) is a very rare disorder with distinct clinical features and can occur in patients with malignancy or autoimmune diseases.
  • We report a 72-year-old male patient with polyarteritis nodosa treated continuously for 5 years with aggressive immunosuppressive drugs, including cyclophosphamide, who experienced three episodes of acute hearing loss during treatment.
  • Organic lesions of the external and middle ear were excluded by repeated examinations, and if one subscribes to McCabe's (Ann Otol Rhinol Laryngol 88:585-589, 1979) definition of AIED, this condition must be considered as the likely cause of the hearing loss.
  • During the period of treatment, three episodes of AIED occurred, and eventually, lung cancer developed.
  • From the time relationship and clinical manifestations of neuropathy and livedo reticularis, the first episode of hearing loss was more likely to be related to vasculitis itself, while the third episode may well have been associated with the development of lung cancer given the dramatic improvement in the clinical condition following treatment of the tumor by excision and cancer chemotherapy.
  • For those patients with autoimmune disease who are on long-term immunosuppressive drug therapy, active surveillance for a nascent malignant tumor should be exercised if AIED recurs or persists.


7. García González LA, Redondo Ventura F: [Metastases in both internal auditive meatus of nasosinusal melanoma]. An Otorrinolaringol Ibero Am; 2005;32(6):537-44
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Metastasis en ambos conductos auditivos internos de melanoma nasosinusal. A propósito de un caso.
  • Primary malignant melanoma of the nasal and paranasal sinusses is rare and represent 3% of malignant nasosinusal tumors.
  • The prognosis of this tumor is poor.
  • Chemotherapy is used for metastatic forms.
  • We present a case of a patient with a primary malignant melanoma of the nasal mucosa.
  • Tree years after diagnosis we found intracranial metastases in left and right auditive internal meatus.
  • [MeSH-major] Ear Neoplasms / secondary. Ear, Inner / pathology. Melanoma / secondary. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475540.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Hazarika P: Solitary malignant schwanoma of para pharyngeal space-a case report and review of literature. Indian J Otolaryngol Head Neck Surg; 2003 Oct;55(4):277-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary malignant schwanoma of para pharyngeal space-a case report and review of literature.
  • Malignnant Schwannom is an aggressive tissue tumor that is more cnmitutnh found m assoiiatiun with Ion Recklinghausens disease.
  • Parupharyngeui tumors are rare and a majority af these are benign salivary or neurogenie tumors, A malignant Schwannoma at this site is very infrequent with only four earn reported so far.
  • The tase of a 16 year old girl with a parapharynccal malignant Schwnnaomu is presented Jor its rarity and our experience in dealing with it. .A combined modallty oftretument with surttery, radiotherapy and chemotherapy Was used.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol. 1979 May;105(5):267-70 [435150.001]
  • [Cites] Laryngoscope. 1991 Oct;101(10):1044-9 [1921630.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Cancer. 1963 Aug;16:1003-14 [14050004.001]
  • [Cites] Ann Surg. 1970 Mar;171(3):419-28 [5416584.001]
  • [Cites] Cancer. 1981 May 15;47(10):2503-9 [6791802.001]
  • [Cites] Ear Nose Throat J. 1988 Feb;67(2):103-7, 110 [3349955.001]
  • (PMID = 23120001.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451183
  • [Keywords] NOTNLM ; Malignant Schwannoma / Parapharyngeal Space Tumors
  •  go-up   go-down


9. Roland JT Jr, Cosetti M, Liebman T, Waltzman S, Allen JC: Cochlear implantation following treatment for medulloblastoma. Laryngoscope; 2010 Jan;120(1):139-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cochlear implantation following treatment for medulloblastoma.
  • OBJECTIVES/HYPOTHESIS: Medulloblastoma is the most common pediatric malignant tumor of the central nervous system in children.
  • Treatment includes surgical excision, external beam radiation, and multiagent chemotherapy.
  • Otologic sequelae are common and may result from radiation and/or chemotherapy.
  • Profound sensorineural hearing loss (SNHL) is a known complication of neuro-oncologic treatment and may render these patients eligible for cochlear implantation (CI).
  • Issues of CI in this population, including diagnosis, treatment of preoperative middle ear disease, operative and postoperative course, performance data, and long-term tumor surveillance are highlighted and reviewed.
  • METHODS: Three patients treated for pediatric medulloblastoma with surgical resection, postoperative hyperfractioned craniospinal radiotherapy, and multiagent adjuvant chemotherapy who underwent cochlear implantation were identified.
  • Details of neuro-oncologic treatment and associated otologic complications are presented and analyzed.
  • Primary outcome assessment includes treatment of middle ear pathology, perioperative cochlear implant course, and postimplantation performance data.
  • RESULTS: Each patient required surgical treatment of chronic ear disease 4 to 16 years after chemoradiation.
  • All progressed to profound SNHL and were implanted 8 to 17 years post-neuro-oncologic treatment.
  • One patient developed postoperative wound dehiscence requiring operative closure.
  • Successful management of middle ear and mastoid pathology involves consideration of potential future cochlear implantation.
  • [MeSH-major] Brain Neoplasms / therapy. Cochlear Implantation. Hearing Loss, Sensorineural / surgery. Medulloblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Humans. Retrospective Studies. Treatment Outcome


10. Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JD Jr, Dores GM, Gilbert ES: Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst; 2005 Sep 21;97(18):1354-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.
  • BACKGROUND: Although second primary cancers are a leading cause of death among men with testicular cancer, few studies have quantified risks among long-term survivors.
  • METHODS: Within 14 population-based tumor registries in Europe and North America (1943-2001), we identified 40,576 1-year survivors of testicular cancer and ascertained data on any new incident solid tumors among these patients.
  • The relative risk and EAR decreased with increasing age at testicular cancer diagnosis (P < .001); the EAR increased with attained age (P < .001) but the excess RR decreased.
  • Among 10-year survivors diagnosed with testicular cancer at age 35 years, the risk of developing a second solid tumor was increased (RR = 1.9, 95% confidence interval [CI] = 1.8 to 2.1).
  • We observed statistically significantly elevated risks, for the first time, for cancers of the pleura (malignant mesothelioma; RR = 3.4, 95% CI = 1.7 to 5.9) and esophagus (RR = 1.7, 95% CI = 1.0 to 2.6).
  • Statistically significantly increased risks of solid cancers were observed among patients treated with radiotherapy alone (RR = 2.0, 95% CI = 1.9 to 2.2), chemotherapy alone (RR = 1.8, 95% CI = 1.3 to 2.5), and both (RR = 2.9, 95% CI = 1.9 to 4.2).
  • For patients diagnosed with seminomas or nonseminomatous tumors at age 35 years, cumulative risks of solid cancer 40 years later (i.e., to age 75 years) were 36% and 31%, respectively, compared with 23% for the general population.
  • CONCLUSIONS: Testicular cancer survivors are at statistically significantly increased risk of solid tumors for at least 35 years after treatment.
  • The statistically significantly increased risk of malignant mesothelioma in testicular cancer survivors has, to our knowledge, not been observed previously in a cohort of patients treated with radiotherapy.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Chemotherapy, Adjuvant / adverse effects. Colonic Neoplasms / epidemiology. Confidence Intervals. Esophageal Neoplasms / epidemiology. Europe / epidemiology. Humans. Incidence. Kidney Neoplasms / epidemiology. Lung Neoplasms / epidemiology. Male. Mesothelioma / epidemiology. Middle Aged. North America / epidemiology. Odds Ratio. Pancreatic Neoplasms / epidemiology. Pleural Neoplasms / epidemiology. Poisson Distribution. Radiotherapy / adverse effects. Radiotherapy, Adjuvant / adverse effects. Registries. Risk Assessment. Stomach Neoplasms / epidemiology. Urinary Bladder Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174857.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Sanders KW, Fowler MR, Milner J, Stucker FJ, Nathan CO: Aggressive fibromatosis of the parapharyngeal space: two cases and treatment recommendations. Ear Nose Throat J; 2004 Apr;83(4):262, 264, 266 passim
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive fibromatosis of the parapharyngeal space: two cases and treatment recommendations.
  • Aggressive fibromatosis is an uncommon tumor that is locally aggressive but not malignant.
  • Therefore, its classification falls between the benign and malignant neoplasms of soft-tissue origin.
  • The treatment of choice is wide surgical excision, which is often difficult.
  • Nonsurgical treatment includes radiation and chemotherapy, both of which are usually reserved for recurrences.
  • We describe two cases of aggressive fibromatosis of the parapharyngeal space, and we review the available treatment options.
  • [MeSH-major] Fibromatosis, Aggressive / diagnosis. Fibromatosis, Aggressive / therapy. Pharyngeal Neoplasms / diagnosis. Pharyngeal Neoplasms / therapy. Pharynx / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Connective Tissue / pathology. Diagnosis, Differential. Female. Humans. Male. Otorhinolaryngologic Surgical Procedures. Recurrence


12. Torkos A, Jóri J, Tóth F, Szamosközi A, Kiss JG, Czigner J: Successful cochlear implantation in a child after recovery from a head and neck malignancy: a case report. Eur Arch Otorhinolaryngol; 2002 Aug;259(7):343-6
MedlinePlus Health Information. consumer health - Meningitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a successful pediatric cochlear implantation that was carried out following bilateral perilingual deafness caused by meningitis during the treatment of a childhood malignant tumor.
  • He then received 11 months of postoperative cytostatic treatment.
  • A purulent meningitis developed at the end of the chemotherapy, resulting in a major-grade, bilateral sensorineural hearing loss (practically a perilingual deafness).
  • After 6 tumor-free years and a meticulous preoperative assessment, a Nucleus 24 M cochlear implant was successfully implanted in the child's left ear.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Cochlear Implantation. Hearing Loss, Sensorineural / etiology. Hearing Loss, Sensorineural / surgery. Meningitis / chemically induced. Meningitis / complications. Rhabdomyosarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12189398.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Taş A, Yağiz R, Koçyiğit M, Karasalihoğlu AR: Primary nasopharyngeal tuberculosis. Kulak Burun Bogaz Ihtis Derg; 2009 Mar-Apr;19(2):109-11
MedlinePlus Health Information. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is hard to differenciate the diagnosis of tuberculosis from nasopharyngeal carcinoma.
  • Histologic and bacteriologic evaluation is required for diagnosis.
  • Clinical presentation of the patient was similar to that of a malignant tumor of the nasopharynx.
  • Histologic and bacteriologic study supported the diagnosis of tuberculosis.
  • After anti-tuberculosis therapy, the complaints of the patient regressed.
  • [MeSH-major] Antitubercular Agents / therapeutic use. Nasopharyngeal Diseases / pathology. Tuberculosis / pathology
  • [MeSH-minor] Biopsy. Drug Therapy, Combination. Humans. Magnetic Resonance Imaging. Male. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19796011.001).
  • [ISSN] 1300-7475
  • [Journal-full-title] Kulak burun boğaz ihtisas dergisi : KBB = Journal of ear, nose, and throat
  • [ISO-abbreviation] Kulak Burun Bogaz Ihtis Derg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


14. Karapantzos I, Tsaroucha A, Polychronidis A, Simopoulos C, Simasko N: Merkel cell carcinoma: report of seven cases. ORL J Otorhinolaryngol Relat Spec; 2003 Nov-Dec;65(6):370-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Merkel cell carcinoma (MCC) is an infrequent, highly malignant, primary skin tumor derived from neuroendocrine cells.
  • All patients had local excision of the tumor.
  • Five patients received adjuvant radiotherapy and 3 of them also received chemotherapy.
  • The patient with the stage III tumor had a survival of 7 months.
  • MCC is a skin tumor with very poor prognosis and high recurrence and metastatic rates.
  • Its treatment is still under discussion.
  • Radical excision of the tumor is the main method of treatment.
  • Superficial parotidectomy seems necessary, especially if the tumor is on the auricle.
  • Adjuvant radio- and chemotherapy may extend survival in case of small-size tumors.
  • [MeSH-major] Carcinoma, Merkel Cell / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Dermatologic Surgical Procedures. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14981332.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


15. Sattar HA, Yang DL, Husain AN, Redleaf MI, Dayal VS: Multiple paragangliomata of the lungs and temporal bone. Ear Nose Throat J; 2008 Nov;87(11):E4-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient's lung lesions did not regress with chemotherapy.
  • A finding of multiple lung paragangliomata should raise the suspicion of a multicentric rather than malignant tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19006054.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Teppone M, Avakyan R: Extremely high-frequency therapy in oncology. J Altern Complement Med; 2010 Nov;16(11):1211-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely high-frequency therapy in oncology.
  • OBJECTIVE: This article represents a review of the literature, mainly from Russian sources, dealing with the therapeutic application of low-intensity electromagnetic radiation in the millimeter band applied to experimental and clinical oncology.
  • METHOD: At the early stage of these studies, efficacy and safety of millimeter electromagnetic radiation (extremely high frequency [EHF]) was proved for various types of malignant tumors.
  • The majority of the further studies demonstrated the high efficacy and safety of millimeter wave radiation in treating patients suffering from both benign and malignant tumors.
  • RESULTS: Developments led to treatment on skin melanoma, cancer of the ear-nose-throat, bowel and breast cancer, cancer of the uterus, lung, and stomach, solid tumors, as well as lymphoma.
  • The main indications for this therapy are (1) preparation prior to radical treatment;.
  • (2) prevention and treatment of side-effects and complications from chemotherapy and radiotherapy;.
  • (3) prevention of metastases, relapses, and dissemination of the tumor;.
  • (4) treatment of the paraneoplastic syndrome; and (5) palliative therapy of incurable patients.
  • CONCLUSIONS: In spite of the fact that not all mechanisms underlying effects of EHF therapy are known as yet, this therapeutic modality has been shown to have great potential in clinical oncology from studies performed in Eastern Europe and Russia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973733.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


17. Greve J, Bas M, Schipper J, Hoffmann TK: [Primary cutane manifestation of a precursor-B-lymphoblastic lymphoma in the external ear]. Laryngorhinootologie; 2008 Oct;87(10):728-30
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cutane manifestation of a precursor-B-lymphoblastic lymphoma in the external ear].
  • [Transliterated title] Primäre kutane Manifestation eines Vorläufer-B-lymphoblastischen Lymphoms im Bereich des äusseren Ohres.
  • A Non-Hodgkin Lymphoma (NHL) represents nearly three percent of all malignant tumors.
  • We report on an extranodal B-cell-lymphoma of the ear in a young woman.
  • This infection led to the development of a massive ear tumor.
  • Histologic examination resulted in the final diagnosis.
  • In spite of the considerable extent of the lymphoma there was no systemic manifestation and a total remission was induced by chemotherapy before adjuvant radiation.
  • [MeSH-major] Ear Neoplasms / diagnosis. Ear, External. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Body Piercing / adverse effects. Combined Modality Therapy. Female. Humans. Radiotherapy, Adjuvant. Wound Infection / complications. Wound Infection / etiology. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633860.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Palma S, Cavazzini L, Bovo R, Padovani D, Bugli AM, Borrelli M, Martini A: Merkel cell tumour of the external ear. Report of a case. Auris Nasus Larynx; 2007 Jun;34(2):229-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell tumour of the external ear. Report of a case.
  • To our best knowledge 20 cases originated from the auricle have been described, 2 of them arising from external ear canal.
  • The authors report a case of the ear canal characterized by two others synchronous tumours and the occurrence of a malignant high grade lymphoma, in which contribute of the pathologist was essential for a critical review.
  • MCC diagnosis is not always easy for its pathological and clinical features and it should always be considered in presence of lymphoma.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Ear Neoplasms / diagnosis. Ear, External
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Fatal Outcome. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / therapy. Humans. Keratins / analysis. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / therapy. Magnetic Resonance Imaging. Male. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / pathology. Parotid Gland / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064866.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


19. Gallo A, Suriano M, Simonelli M, Ralli G, de Vincentiis M: Recurrent malignant schwannoma of the parapharyngeal space in neurofibromatosis type 1. Ear Nose Throat J; 2003 Nov;82(11):862-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent malignant schwannoma of the parapharyngeal space in neurofibromatosis type 1.
  • Malignant schwannoma is an aggressive tumor that carries a poor prognosis despite wide excision, chemotherapy, and radiotherapy.
  • Malignant schwannoma of the parapharyngeal space is an uncommon finding; to our knowledge, only four cases have been described in the literature during the past 30 years, and only one of them involved a patient who had clinical evidence of neurofibromatosis type 1.
  • In this article, we describe a new case of malignant schwannoma of the parapharyngeal space in a patient who had clinical evidence of neurofibromatosis type 1.
  • Following resection of the tumor and a total parotidectomy, the diagnosis was made on the basis of histology and immunohistochemistry.
  • The patient underwent postoperative chemotherapy with carboplatin and UP16.
  • However, 5 months following surgery, the tumor recurred and metastasized.
  • The IVA2 regimen slowed tumor growth, but 13 months after the initiation of therapy, the patient died of neoplastic cachexia.
  • Although chemotherapy is generally ineffective in most cases of malignant schwannoma, we did experience some positive results with the IVA2 protocol.
  • Therefore, we recommend that this combination be considered as a first-line adjuvant therapy following surgery or as a first-line therapy for patients with inoperable tumors.
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local


20. Shuto J, Ueyama T, Suzuki M, Mogi G: Primary lymphoma of bilateral external auditory canals. Am J Otolaryngol; 2002 Jan-Feb;23(1):49-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistopathologic examination and immunoglobulin heavy chain gene rearrangement studies led to a diagnosis of B-cell lymphoma.
  • After chemotherapy, total gross tumor removal by surgery was achieved, and no recurrence has been detected during 1 year of follow-up.
  • To our knowledge, this is the third case of malignant lymphoma originating in the external auditory canal to be reported in the literature, and this is the first report that includes immunohistochemical findings of fresh tissue.
  • [MeSH-major] Ear Canal / pathology. Ear Canal / radiography. Ear Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Hearing Loss, Sensorineural / diagnosis. Hearing Loss, Sensorineural / etiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Otologic Surgical Procedures / methods. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11791249.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Cankaya H, Ugras S, Dilek I: Head and neck granulocytic sarcoma with acute myeloid leukemia: three rare cases. Ear Nose Throat J; 2001 Apr;80(4):224-6, 228-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was administered chemotherapy and radiotherapy, but he died of infection secondary to a second relapse 29 months after the initial diagnosis.
  • A 17-year-old girl had a tumor in the right parotid area.
  • She received chemotherapy, but she died of infection and bleeding 2 months after the initial diagnosis.
  • He received chemotherapy and was in remission 12 months after the initial diagnosis, but he eventually relapsed and died.
  • This tumor is very often misdiagnosed as a malignant lymphoma, which leads to delayed treatment and a poor outcome.
  • Therefore, clinical and histopathologic findings should be evaluated before any diagnosis of malignant lymphoma is pronounced.
  • Immunohistochemical stains should also be performed on patients with suspected granulocytic sarcoma, and aggressive chemotherapy or immunotherapy should be administered.
  • We believe that high-dose chemotherapy can improve survival rates in granulocytic sarcoma associated with AML.
  • [MeSH-minor] Adolescent. Adult. Diagnostic Errors. Facial Paralysis / etiology. Fatal Outcome. Female. Humans. Immunohistochemistry. Male. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11338646.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Dumesnil C, Gatbois E, Leverger G: [Infantile choriocarcinoma: an uncommon and curable tumor]. Arch Pediatr; 2005 Dec;12(12):1721-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Infantile choriocarcinoma: an uncommon and curable tumor].
  • [Transliterated title] Le choriocarcinome infantile : une tumeur exceptionnelle et curable.
  • Choriocarcinoma is a malignant growth of trophoblastic cells characterized by secretion of human chorionic gonadotropin (hCG).
  • Infantile choriocarcinoma is a very rare tumor, which is a complication of gestational choriocarcinoma and usually had very poor prognosis before chemotherapy was used.
  • Our case report describes the successful treatment by chemotherapy of a newborn with cerebral metastasis.
  • Anemia, hepatomegaly and hemorrhagic syndromes are the main symptoms with sometimes cerebral, cutaneous or ear-nose and throat localisations.
  • But diagnosis can be difficult when clinical symptoms are poor.
  • Histological pattern is not mandatory for diagnosis.
  • Recommended treatment is chemotherapy and surgery is discussed when a tumoral residue remains.
  • Post-treatment surveillance is based on clinical and radiological examination as well as negativation of beta-hCG.
  • Infantile choriocarcinoma is a very chemosensitive tumor and is thereby potentially curable.
  • Early diagnosis is the most important prognostic factor.
  • [MeSH-minor] Chorionic Gonadotropin, beta Subunit, Human / analysis. Diagnosis, Differential. Female. Humans. Infant, Newborn. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271451.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


24. Yee LL, Keng CG: A rare case of renal cell carcinoma metastatic to the sinonasal area. Ear Nose Throat J; 2001 Jul;80(7):462-7
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After radiotherapy had failed to arrest the tumor's growth, the mass was removed via a craniofacial resection.
  • This case illustrates the importance of (1) a high index of suspicion in differentiating this rare tumor from other benign or malignant diseases, (2) awareness of the risk of hemorrhage and the role of preoperative embolization, (3) the need for paraffin histology rather than fine-needle aspiration or frozen section diagnosis, (4) individualizing therapy after due consideration of the characteristics of both the patient and the tumor, and (5) keeping abreast of the most current therapeutic modalities so that patient management can be individualized and optimized.
  • Surgical excision offers the best hope for long-term survival, and it reduces the degree of pain, epistaxis, and disfigurement from the expanding tumor.
  • When such tumors are not resectable, management with radiotherapy, hormonal therapy, immunotherapy, or chemotherapy can be considered.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Embolization, Therapeutic / methods. Kidney Neoplasms / pathology. Nasal Cavity / pathology. Nose Neoplasms / secondary. Nose Neoplasms / surgery. Otorhinolaryngologic Surgical Procedures
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Prognosis. Recurrence. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11480304.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Word R, Urquhart AC, Ejercito VS: Primary laryngeal lymphoma: case report. Ear Nose Throat J; 2006 Feb;85(2):109-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathology of a deep biopsy specimen identified a malignant, diffuse, CD20-positive, B-cell lymphoma.
  • The stage IE lymphoma completely resolved after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and rituximab.
  • Despite its relative rarity, the consequences of a missed diagnosis warrant vigilance for this type of laryngeal tumor.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / drug therapy. Lymphoma / diagnosis. Lymphoma / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Hoarseness. Humans. Laryngoscopy. Male. Prednisone / therapeutic use. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / therapeutic use. Vocal Cords / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579200.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


26. Alobid I, Gastón F, Morello A, Guilemany JM, Mullol J: Peripheral primitive neuroectodermal tumor of the cerebellopontine angle. Acta Otolaryngol; 2005 Apr;125(4):426-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral primitive neuroectodermal tumor of the cerebellopontine angle.
  • Peripheral primitive neuroectodermal tumors are highly malignant small cell neoplasms.
  • The patient was treated with chemotherapy (etoposide, vincristine, adriamycin, ifosfamide and actinomycin D) and radiotherapy.
  • Radical cervical dissection was performed and the patient was treated with a second course of chemotherapy.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Ear, Inner / pathology. Ear, Inner / surgery. Female. Follow-Up Studies. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Retreatment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823816.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


27. Meyer TK, Rhee JS, Smith MM, Cruz MJ, Osipov VO, Wackym PA: External auditory canal eccrine spiradenocarcinoma: a case report and review of literature. Head Neck; 2003 Jun;25(6):505-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This tumor demonstrates highly malignant biologic behavior with a high recurrence rate, frequent lymph node metastases, and overall poor survival.
  • The management of this tumor, its histopathologic characteristics, and a review of literature are presented.
  • Local recurrence occurred in 58.8% of patients, with an average of 23 months from diagnosis.
  • Lymph node metastasis occurred in 35.3%, with an average of 31 months from diagnosis.
  • CONCLUSIONS: Eccrine spiradenocarcinoma is an aggressive tumor with a poor prognosis.
  • Primary treatment should include wide local excision with or without regional lymphadenectomy.
  • Isolated successful treatments have been documented with adjuvant hormonal manipulation, chemotherapy, and radiation therapy.
  • [MeSH-major] Ear Canal / pathology. Ear Neoplasms / diagnosis. Neoplasms, Adnexal and Skin Appendage / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley Periodicals, Inc.
  • (PMID = 12784243.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


28. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lübbe AS: Locoregional cancer treatment with magnetic drug targeting. Cancer Res; 2000 Dec 1;60(23):6641-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locoregional cancer treatment with magnetic drug targeting.
  • The specific delivery of chemotherapeutic agents to their desired targets with a minimum of systemic side effects is an important, ongoing challenge of chemotherapy.
  • One approach, developed in the past to address this problem, is the i.v. injection of magnetic particles [ferrofluids (FFs)] bound to anticancer agents that are then concentrated in the desired area (e.g., the tumor) by an external magnetic field.
  • When the tumor had reached a volume of approximately 3500 mm3, FF-MTX was injected intraarterially (i.a.
  • ; femoral artery) or i.v. (ear vein), whereas an external magnetic field was focused on the tumor.
  • FF-MTX i.a. application with the external magnetic field resulted in a significant (P < 0.05), complete, and permanent remission of the squamous cell carcinoma compared with the control group (no treatment) and the i.v.
  • This "magnetic drug targeting" offers a unique opportunity to treat malignant tumors locoregionally without systemic toxicity.
  • Furthermore, it may be possible to use these magnetic particles as a "carrier system" for a variety of anticancer agents, e.g., radionuclides, cancer-specific antibodies, and genes.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Delivery Systems. Magnetics. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / metabolism
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Colloids / administration & dosage. Colloids / pharmacokinetics. Drug Carriers. Female. Ferric Compounds / administration & dosage. Ferric Compounds / pharmacokinetics. Magnetic Resonance Imaging. Mitoxantrone / administration & dosage. Mitoxantrone / pharmacokinetics. Rabbits

  • Hazardous Substances Data Bank. FERRIC OXIDE .
  • Hazardous Substances Data Bank. HEMATITE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11118047.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Colloids; 0 / Drug Carriers; 0 / Ferric Compounds; 1K09F3G675 / ferric oxide; 2UA751211N / ferric hydroxide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


29. Kumar S, Gupta AK, Yadav BS, Ghoshal S: Primary sinonasal malignant melanoma: a clinicopathologic and prognostic study. Ear Nose Throat J; 2009 Dec;88(12):1269-72
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sinonasal malignant melanoma: a clinicopathologic and prognostic study.
  • We conducted a retrospective study to evaluate the clinicopathologic features and prognostic factors associated with primary sinonasal malignant melanoma.
  • Medial maxillectomy was performed in 4 patients, wide local excision in 3, and endoscopic excision in 2; the remaining patient, who had presented with a liver metastasis, received chemotherapy and palliative local radiotherapy.
  • Based on the findings of our small study, we conclude that primary sinonasal malignant melanoma carries a generally poor prognosis despite aggressive treatment.
  • Other factors that appeared to be associated with a poor prognosis were (1) older age, (2) a primary tumor location in a paranasal sinus, (3) an advanced tumor stage, (4) an external approach to surgery, and (5) the absence of adjuvant radiotherapy.
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013681.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Holden B, Colome-Grimmer M, Savage C, Stierman K, Pou AM: Malignant eccrine acrospiroma with metastasis to the parotid. Ear Nose Throat J; 2002 May;81(5):352-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant eccrine acrospiroma with metastasis to the parotid.
  • Malignant eccrine acrospiromas are rare.
  • (1) malignant transformation can occur, (2) the presence of both benign and malignant tissue can lead to a false-negative diagnosis if only the benign component is obtained in the biopsy specimen, and (3) benign-appearing tumors can recur locally or metastasize.
  • The primary treatment is wide local excision with or without lymph node dissection.
  • The efficacy of adjuvant chemotherapy and radiation therapy requires further investigation.
  • We describe a case of malignant eccrine acrospiroma in an 80-year-old man, and we review the literature on this tumor, with emphasis on the differential diagnosis.

  • Genetic Alliance. consumer health - Acrospiroma.
  • Genetic Alliance. consumer health - Eccrine Acrospiroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12025008.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement